🇺🇸 FDA
Pipeline program

GT719 Injection

GRIT-CD-CHN-719-001-056

Phase 2 mab active

Quick answer

GT719 Injection for Hematological Malignancy (Leukemia- Lymphoma) is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Hematological Malignancy (Leukemia- Lymphoma)
Phase
Phase 2
Modality
mab
Status
active

Clinical trials